<DOC>
	<DOCNO>NCT01475695</DOCNO>
	<brief_summary>Approximately 6 healthy male subject administer single 1500 mg intravenous dose 14C-GSK2251052 fasted condition . Blood , urine fecal sample collect minimum 14 day follow study drug administration . Safety tolerability monitor throughout study . A follow-up visit occur 7-14 day study drug administration .</brief_summary>
	<brief_title>GSK2251052 Mass Balance Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Community-Acquired Infections</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test ECG . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male 30 55 year age inclusive , time signing informed consent . Male subject must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication least 90 day follow dose GSK2251052 . Body weight equal great 50 kg BMI within range 18.530.0 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . QTcB le 450 msec QTc le 480 msec subject Bundle Branch Block . Available complete study return followup visit necessary . A history regular bowel movement ( average one bowel movement per day ) . AST , ALT , alkaline phosphatase bilirubin equal less 1.5xULN ( isolate bilirubin great 1.5xULN acceptable bilirubin fractionate direct bilirubin le 35 % ) . Female subject . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : average weekly intake great 21 unit male great than14 unit female . One unit equivalent 8 g alcohol : halfpint ( approximately 240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice [ and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juice ] 7 day prior first dose study medication . Subjects received total body radiation dose great 5.0 mSv ( upper limit WHO category II ) exposure significant radiation ( e.g . serial xray CT scan , barium meal etc ) 12 month prior study . Any condition could interfere accurate assessment recovery radioactivity [ 14C ] . Participation clinical trial involve administration 14Clabelled compound ( ) within last 12 month . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . The subject 's systolic blood pressure outside range 90140 mmHg , diastolic blood pressure outside range 4590 mmHg heart rate outside range 45100 bpm . A single repeat allow determine eligibility . Exclusion criterion screen ECG per protocol . ( single repeat allow eligibility determination ) .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Mass balance</keyword>
	<keyword>intravenous</keyword>
	<keyword>GSK2251052</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Antimicrobial</keyword>
	<keyword>Radiolabel</keyword>
</DOC>